
Neurogene Inc (NGNE) Stock Forecast & Price Target
Neurogene Inc (NGNE) Analyst Ratings
Bulls say
Neurogene is a clinical-stage biotechnology company that has a differentiated product portfolio of genetic medicines for rare neurological diseases, mainly focusing on Rett syndrome and CLN5 Batten disease. The company's proprietary transgene regulation technology, EXACT, has shown strong results in clinical trials, with patients experiencing increases in developmental milestones and improvements in daily function. With a 70% probability of success for their lead drug candidate NGN-401 and an increased market share estimate, Neurogene is poised for growth with a projected 2032 market share of 65%. The company's strong data and progress in both its Phase 1/2 study and the ongoing registrational study for NGN-401 are key catalysts for future success, and with a Buy rating and a 12-month price target of $70, Neurogene's stock is a promising investment opportunity.
Bears say
Neurogene is currently trading at a premium valuation compared to its peers in the biotech industry, and its future success is heavily dependent on the performance of its two drug candidates, which are still in the early stages of development. While the company's EXACT platform shows promise in treating Rett syndrome, it is also facing competition from other companies such as Taysha with their own treatments in the pipeline. In order to close the valuation gap, Neurogene will need to continue to execute and reach key milestones, such as FDA feedback and successful clinical trial results for Embolden.
This aggregate rating is based on analysts' research of Neurogene Inc and is not a guaranteed prediction by Public.com or investment advice.
Neurogene Inc (NGNE) Analyst Forecast & Price Prediction
Start investing in Neurogene Inc (NGNE)
Order type
Buy in
Order amount
Est. shares
0 shares